Literature DB >> 26195521

Robust Algorithm for Systematic Classification of Malaria Late Treatment Failures as Recrudescence or Reinfection Using Microsatellite Genotyping.

Mateusz M Plucinski1, Lindsay Morton2, Mary Bushman3, Pedro Rafael Dimbu4, Venkatachalam Udhayakumar2.   

Abstract

Routine therapeutic efficacy monitoring to measure the response to antimalarial treatment is a cornerstone of malaria control. To correctly measure drug efficacy, therapeutic efficacy studies require genotyping parasites from late treatment failures to differentiate between recrudescent infections and reinfections. However, there is a lack of statistical methods to systematically classify late treatment failures from genotyping data. A Bayesian algorithm was developed to estimate the posterior probability of late treatment failure being the result of a recrudescent infection from microsatellite genotyping data. The algorithm was implemented using a Monte Carlo Markov chain approach and was used to classify late treatment failures using published microsatellite data from therapeutic efficacy studies in Ethiopia and Angola. The algorithm classified 85% of the Ethiopian and 95% of the Angolan late treatment failures as either likely reinfection or likely recrudescence, defined as a posterior probability of recrudescence of <0.1 or >0.9, respectively. The adjusted efficacies calculated using the new algorithm differed from efficacies estimated using commonly used methods for differentiating recrudescence from reinfection. In a high-transmission setting such as Angola, as few as 15 samples needed to be genotyped in order to have enough power to correctly classify treatment failures. Analysis of microsatellite genotyping data for differentiating between recrudescence and reinfection benefits from an approach that both systematically classifies late treatment failures and estimates the uncertainty of these classifications. Researchers analyzing genotyping data from antimalarial therapeutic efficacy monitoring are urged to publish their raw genetic data and to estimate the uncertainty around their classification.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26195521      PMCID: PMC4576024          DOI: 10.1128/AAC.00072-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Twelve microsatellite markers for characterization of Plasmodium falciparum from finger-prick blood samples.

Authors:  T J Anderson; X Z Su; M Bockarie; M Lagog; K P Day
Journal:  Parasitology       Date:  1999-08       Impact factor: 3.234

2.  Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy.

Authors:  Madeline Slater; Moses Kiggundu; Chris Dokomajilar; Moses R Kamya; Nathan Bakyaita; Ambrose Talisuna; Philip J Rosenthal; Grant Dorsey
Journal:  Am J Trop Med Hyg       Date:  2005-08       Impact factor: 2.345

3.  Validation of microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections.

Authors:  Bryan Greenhouse; Alissa Myrick; Christian Dokomajilar; Jonathan M Woo; Elaine J Carlson; Philip J Rosenthal; Grant Dorsey
Journal:  Am J Trop Med Hyg       Date:  2006-11       Impact factor: 2.345

4.  Impact of transmission intensity on the accuracy of genotyping to distinguish recrudescence from new infection in antimalarial clinical trials.

Authors:  Bryan Greenhouse; Christian Dokomajilar; Alan Hubbard; Philip J Rosenthal; Grant Dorsey
Journal:  Antimicrob Agents Chemother       Date:  2007-06-25       Impact factor: 5.191

Review 5.  Spread and evolution of Plasmodium falciparum drug resistance.

Authors:  Toshihiro Mita; Kazuyuki Tanabe; Kiyoshi Kita
Journal:  Parasitol Int       Date:  2009-04-23       Impact factor: 2.230

6.  The perils of PCR: can we accurately 'correct' antimalarial trials?

Authors:  Jonathan J Juliano; Nahla Gadalla; Colin J Sutherland; Steven R Meshnick
Journal:  Trends Parasitol       Date:  2010-01-18

7.  Artemisinin resistance in Plasmodium falciparum malaria.

Authors:  Arjen M Dondorp; François Nosten; Poravuth Yi; Debashish Das; Aung Phae Phyo; Joel Tarning; Khin Maung Lwin; Frederic Ariey; Warunee Hanpithakpong; Sue J Lee; Pascal Ringwald; Kamolrat Silamut; Mallika Imwong; Kesinee Chotivanich; Pharath Lim; Trent Herdman; Sen Sam An; Shunmay Yeung; Pratap Singhasivanon; Nicholas P J Day; Niklas Lindegardh; Duong Socheat; Nicholas J White
Journal:  N Engl J Med       Date:  2009-07-30       Impact factor: 91.245

8.  Clinical manifestations of new versus recrudescent malaria infections following anti-malarial drug treatment.

Authors:  Ayesha M Shaukat; Elizabeth A Gilliams; Leo J Kenefic; Matthew B Laurens; Fraction K Dzinjalamala; Osward M Nyirenda; Phillip C Thesing; Christopher G Jacob; Malcolm E Molyneux; Terrie E Taylor; Christopher V Plowe; Miriam K Laufer
Journal:  Malar J       Date:  2012-06-18       Impact factor: 2.979

Review 9.  Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria.

Authors:  Kasia Stepniewska; Nicholas J White
Journal:  Malar J       Date:  2006-12-22       Impact factor: 2.979

10.  In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia.

Authors:  Jimee Hwang; Bereket Hailegiorgis Alemayehu; Richard Reithinger; Samuel Girma Tekleyohannes; Sintayehu Gebresillasie Birhanu; Leykun Demeke; David Hoos; Zenebe Melaku; Moges Kassa; Daddi Jima; Joseph L Malone; Henry Nettey; Michael Green; Amanda Poe; Sheila Akinyi; Venkatachalam Udhayakumar; S Patrick Kachur; Scott Filler
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

View more
  19 in total

1.  Classification of disease recurrence using transition likelihoods with expectation-maximization algorithm.

Authors:  Huijun Jiang; Quefeng Li; Jessica T Lin; Feng-Chang Lin
Journal:  Stat Med       Date:  2022-07-31       Impact factor: 2.497

2.  A Computer Modelling Approach To Evaluate the Accuracy of Microsatellite Markers for Classification of Recurrent Infections during Routine Monitoring of Antimalarial Drug Efficacy.

Authors:  Sam Jones; Mateusz Plucinski; Katherine Kay; Eva Maria Hodel; Ian M Hastings
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

3.  Plasmodium falciparum HRP2 ELISA for analysis of dried blood spot samples in rural Zambia.

Authors:  Lauren E Gibson; Christine F Markwalter; Danielle W Kimmel; Lwiindi Mudenda; Saidon Mbambara; Philip E Thuma; David W Wright
Journal:  Malar J       Date:  2017-08-23       Impact factor: 2.979

Review 4.  Tools for surveillance of anti-malarial drug resistance: an assessment of the current landscape.

Authors:  Christian Nsanzabana; Djibrine Djalle; Philippe J Guérin; Didier Ménard; Iveth J González
Journal:  Malar J       Date:  2018-02-08       Impact factor: 2.979

5.  Efficacy and safety of artesunate-amodiaquine and artemether-lumefantrine and prevalence of molecular markers associated with resistance, Guinea: an open-label two-arm randomised controlled trial.

Authors:  Abdoul Habib Beavogui; Alioune Camara; Alexandre Delamou; Mamadou Saliou Diallo; Abdoulaye Doumbouya; Karifa Kourouma; Patrice Bouedouno; Timothée Guilavogui; Samaly Dos Santos Souza; Julia Kelley; Eldin Talundzic; Aissata Fofana; Mateusz M Plucinski
Journal:  Malar J       Date:  2020-06-24       Impact factor: 2.979

6.  Genotyping genetically heterogeneous Cyclospora cayetanensis infections to complement epidemiological case linkage.

Authors:  Joel L N Barratt; Subin Park; Fernanda S Nascimento; Jessica Hofstetter; Mateusz Plucinski; Shannon Casillas; Richard S Bradbury; Michael J Arrowood; Yvonne Qvarnstrom; Eldin Talundzic
Journal:  Parasitology       Date:  2019-06-20       Impact factor: 3.234

7.  Capacity Development through the US President's Malaria Initiative-Supported Antimalarial Resistance Monitoring in Africa Network.

Authors:  Eric S Halsey; Meera Venkatesan; Mateusz M Plucinski; Eldin Talundzic; Naomi W Lucchi; Zhiyong Zhou; Celine I Mandara; Hawela Moonga; Busiku Hamainza; Abdoul Habib Beavogui; Simon Kariuki; Aaron M Samuels; Laura C Steinhardt; Don P Mathanga; Julie Gutman; Yves Eric Denon; Aline Uwimana; Ashenafi Assefa; Jimee Hwang; Ya Ping Shi; Pedro Rafael Dimbu; Ousmane Koita; Deus S Ishengoma; Daouda Ndiaye; Venkatachalam Udhayakumar
Journal:  Emerg Infect Dis       Date:  2017-12       Impact factor: 6.883

Review 8.  Statistical methods to derive efficacy estimates of anti-malarials for uncomplicated Plasmodium falciparum malaria: pitfalls and challenges.

Authors:  Prabin Dahal; Julie A Simpson; Grant Dorsey; Philippe J Guérin; Ric N Price; Kasia Stepniewska
Journal:  Malar J       Date:  2017-10-26       Impact factor: 2.979

9.  Efficacy of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for treatment of uncomplicated Plasmodium falciparum malaria in Angola, 2015.

Authors:  Mateusz M Plucinski; Pedro Rafael Dimbu; Aleixo Panzo Macaia; Carolina Miguel Ferreira; Claudete Samutondo; Joltim Quivinja; Marília Afonso; Richard Kiniffo; Eliane Mbounga; Julia S Kelley; Dhruviben S Patel; Yun He; Eldin Talundzic; Denise O Garrett; Eric S Halsey; Venkatachalam Udhayakumar; Pascal Ringwald; Filomeno Fortes
Journal:  Malar J       Date:  2017-02-02       Impact factor: 2.979

10.  Efficacy and safety of artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017.

Authors:  Elizabeth Davlantes; Pedro Rafael Dimbu; Carolina Miguel Ferreira; Maria Florinda Joao; Dilunvuidi Pode; Jacinto Félix; Edgar Sanhangala; Benjamin Nieto Andrade; Samaly Dos Santos Souza; Eldin Talundzic; Venkatachalam Udhayakumar; Chantelle Owens; Eliane Mbounga; Lubbe Wiesner; Eric S Halsey; José Franco Martins; Filomeno Fortes; Mateusz M Plucinski
Journal:  Malar J       Date:  2018-04-03       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.